Drug intelligence / Profile preview

cNP8

Development stage: Phase 1
Lead developer: Neomatrix Therapeutics
Modality: Peptides
Administration: Intravenous, Topical

Overview

cNP8 is a novel bioactive peptide designed for both intravenous and topical treatment of burns within 8 to 24 hours post-injury. It promotes mesenchymal cell growth, proliferation, and migration in vitro and acts synergistically with growth factors including platelet-derived growth factor-BB. Unlike similar peptides, cNP8 is effective topically because it resists both exopeptidases and neutrophil elastase, which are known to play a major role in Fibronectin degradation in burn wound fluid.

Other names: cNP8cNP-8cNP 8

Targets

HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))Neuraminidase

Beyond the preview

Go deeper on cNP8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cNP8.

Explore the full profile